Form 4: AbbVie Director Robert J. Alpern Reports Changes in Beneficial Ownership

Director Robert J. Alpern reports acquisition and disposal of AbbVie common stock and restricted stock units.

Summary

• On May 3, 2024, Robert J. Alpern, a director of AbbVie Inc., reported changes in beneficial ownership of AbbVie securities.
• Alpern acquired 1,322 shares of common stock.
• Alpern also disposed of 34,443 shares of common stock.
• These transactions involved restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program, which will be paid in shares of AbbVie common stock upon separation from service, death, or a change in control.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, reflecting neutral sentiment. It reports transactions without expressing any positive or negative outlook.

Future Outlook

The restricted stock units will be paid in shares of AbbVie common stock on the earlier of the director's separation from service, death, or the occurrence of a change in control as defined in the Program.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's view of the company's prospects.

Stakeholder Impact

• The transactions may be of interest to shareholders as they provide insight into the actions of a company director.

Key Dates